News&lnfo
RecBio is a high-tech enterprise jointly founded by the former vaccine R & D expert team from the Chinese Center for Disease Control and Prevention (China CDC) and the senior vaccine industrialization team.
The company has established a leading domestic R & D and innovation platform for new adjuvants, genetic engineering, and immune evaluation.

The construction of RecBio industrialization base was started on May 18, 2020

  • Categories:News & Info
  • Author:Reporter Xie Rong Correspondent Liu Haoyu
  • Origin:Taizhou Daily
  • Time of issue:2020-10-27
  • Views:0

(Summary description)As the zone with the highest concentration of vaccine enterprises in China, China Medical City has taken one step closer to the goal of being the "national landmark of the vaccine industry".

The construction of RecBio industrialization base was started on May 18, 2020

(Summary description)As the zone with the highest concentration of vaccine enterprises in China, China Medical City has taken one step closer to the goal of being the "national landmark of the vaccine industry".

  • Categories:News & Info
  • Author:Reporter Xie Rong Correspondent Liu Haoyu
  • Origin:Taizhou Daily
  • Time of issue:2020-10-27
  • Views:0
Information

As the zone with the highest concentration of vaccine enterprises in China, China Medical City has taken one step closer to the goal of being the "national landmark of the vaccine industry". On May 18, the construction of industrialization base project of RecBio was started, with a modern vaccine factory expected to set up in two years. The most remarkable thing is that the base will produce the 9-valent HPV vaccines and recombinant herpes zoster vaccines, both of which are "genetically engineered vaccines for major diseases", aiming at being the "first to be launched in China". This will comprehensively boost the scale and development level of the vaccine industry clustering in China Medical City.

It is worth mentioning that May 18 was also the anniversary of RecBio. On this day in 2012, RecBio was founded in China Medical City. "After eight years, we have formed four product lines with market capacity of tens of billions, including 9-valent HPV vaccines, recombinant herpes zoster vaccines and tuberculosis vaccines." Liu Yong, the general manager of RecBio, told the reporters that the company has received CNY 500 million of series A round financing, strategically led by China Resources Pharmaceutical Industry Fund and followed by CMB International Capital, Oriental Fortune Capital and China Medical City Class I New Drug Fund, with all parties working together to build a new future-oriented advanced vaccine industrialization base.

With the "backing" of various funds, RecBio accelerates its expansion. This industrialization base project has an investment of nearly CNY 600 million and a total construction area of over 100,000 square meters. The first phase of the project includes a production workshop for 9-valent HPV vaccine and its supporting facilities for office, R&D, quality inspection, storage and power, etc. Upon completion, the project will generate an annual production capacity of 5 million doses of 9-valent HPV vaccines. The second phase of the project will include a production workshop for recombinant herpes zoster vaccine with the same designed annual production capacity of 5 million doses. The whole project is expected to start trial production in October 2023 and be formally put into operation in 2024, with sales revenue exceeding CNY 10 billion per year in 5 years.

Currently in China, only imported 9-valent HPV vaccines are available, with insufficient supplies and high prices, while recombinant herpes zoster vaccines are largely unavailable in domestic market.

The R&D cycle of biological drugs is long, while that of vaccines is even longer, which is a complex and systematic process that generally lasts more than 10 years. Among vaccines, the 9-valent HPV vaccines are the ones with relatively long R&D cycles and also require large sample sizes for clinical trials, so they are the products of heavy investment. RecBio is the first in the country to develop the recombinant herpes zoster vaccines. The recombinant herpes zoster vaccines prepared by genetic engineering technology has a higher protection rate compared to conventional vaccines. For example, the protection rate can be increased from 38% to 98% in people over 70 years old.

"The above two vaccines remain undeveloped in China, with many challenges along the way, but we always adhere to the concept of focusing on the industry's high points and only making the leading varieties." Liu Yong introduced that the layout strategy of the company's product line should be "large, high, fast and stable". "'Large' means to target products with large market capacity; 'high' means to use the best technology to make products with the highest performance; 'fast' means to advance product development and project construction at the fastest speed; 'stable' means to use the most advanced and mature technical route to make products achieve the best balance of safety and immune effect."

At present, RecBio's 9-valent HPV vaccines have been successfully scaled up to a commercial scale of 100,000 doses in batch production and 5 million doses in annual production, with a very stable process. The 9-valent HPV vaccine will soon enter phase III clinical trial, which is at the forefront in China. Meanwhile, the development of recombinant herpes zoster vaccine has also entered the pilot stage and will enter the clinic trials next year, with the official launch expected in 2025.

Another encouraging news is that RecBio has formed a sound momentum of rolling development. "In the future, we will have 2 to 3 varieties into clinical trials every year, and the tuberculosis vaccines currently being developed will hopefully fill the global gap." Liu Yong is full of confidence.

In concert with this, RecBio is doing its best to attract more outstanding talents. The reporter learned that in the next three years, the company plans to spend more than CNY 100 million of equity as incentives for outstanding talents. While accelerating the creation of "talent highland", it will also speed up the pooling of technology and capital around talents, so as to create a high-capacity "rich mine" of elemental resources, and continue to empower RecBio to go higher and further.

Scan the QR code to read on your phone

  • TOP   

Contact Us

Jiangsu Rec-Biotechnology Co., Ltd.

tel:+86-523-86818860

 

Address: Vaccine Engineering Center, China Medical City, Taizhou

Copyright © 2020 Jiangsu Rec-Biotechnology Co., Ltd.  All rights reserved.      苏ICP备19043567号-1